Search

Zentalis Pharmaceuticals Inc

Lezárt

4.13 -2.82

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

4.12

Maximum

4.38

Fő mutatók

By Trading Economics

Bevétel

-42M

-78M

Egy részvényre jutó nyereség

-0.59

Munkavállalók

106

EBITDA

-42M

-77M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+105.83% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 6.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-34M

297M

Előző nyitás

6.95

Előző zárás

4.13

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 13. 23:56 UTC

News

Molson Coors Beverage Co shares advanced in after-market hours to $43.20, following Q2 revenues of $3.10 billion that met analyst expectations.

2026. aug. 13. 23:56 UTC

GitLab Inc. shares are trading lower in after-market hours, despite an earlier rebound from session lows. No specific news was identified.

2026. aug. 13. 23:56 UTC

Pegasystems Inc. shares are lower in after-market trading, with no specific news identified. The broader market reacts to rising initial jobless claims.

2026. aug. 13. 23:56 UTC

Zebra Technologies shares are trading higher in after-market hours, maintaining strength above its 20-day moving average and near the upper end of its one-month range.

2026. aug. 13. 23:56 UTC

Correlated Moves

T Rowe Price Group Inc shares are lower in after-market trading, extending a trend of declines over the past three sessions amid broader market weakness.

2026. aug. 13. 23:56 UTC

iShares TIPS Bond ETF traded roughly flat during after-market hours. The asset remains near the lower end of its one-month trading range.

2026. aug. 13. 23:56 UTC

Cherry Hill Mortgage Investment Corp is trading lower in after-market hours, declining from earlier gains despite remaining above its 20-day moving average.

2026. aug. 13. 23:56 UTC

Toast Inc shares are lower in after-market trading. No specific company news was identified to explain this price movement.

2026. aug. 13. 23:56 UTC

Correlated Moves

Skyworks Solutions Inc shares declined in after-market trading, influenced by broader market movements and rising initial jobless claims indicating potential labor market softness.

2026. aug. 13. 23:56 UTC

Shares of Camtek Ltd are trading higher in after-market hours, remaining above their 20-day moving average despite routine performance during the regular session.

2026. aug. 13. 23:56 UTC

NetApp Inc. shares are higher in after-market trading, remaining above their 20-day moving average amid broader market dynamics and rising initial jobless claims.

2026. aug. 13. 23:56 UTC

Correlated Moves

TPG Inc shares declined in after-market trading, settling lower after earlier gains. The drop aligns with a slight decrease in the Russell 2000 Index.

2026. aug. 13. 23:56 UTC

News
Event

Bristol-Myers Squibb's shares are lower after FDA approval of ZENBEXUS for multiple myeloma, amid concerns over drug risks and ongoing trial verification.

2026. aug. 13. 23:56 UTC

Correlated Moves
Macro News
ETF Constituents

iShares MSCI South Korea ETF gains in after-market trading, reflecting KOSPI's surge amid positive sentiment around interest rates and U.S. stock performance.

2026. aug. 13. 23:52 UTC

Kura Oncology Inc is trading higher in after-market hours, reflecting broader market optimism following recent economic data and a stable producer price index.

2026. aug. 13. 23:51 UTC

Tyler Technologies Inc shares are higher in after-market trading, reflecting strong performance since Thursday's close, despite no specific news identified to explain the movement.

2026. aug. 13. 23:51 UTC

Clean Energy Fuels Corp shares are lower in after-market hours, reversing earlier gains amid broader market sentiment influenced by recent economic data.

2026. aug. 13. 23:51 UTC

Gladstone Land Corp. shares rose in after-market trading, recovering from earlier losses amid broader market optimism following unchanged producer price index data.

2026. aug. 13. 23:51 UTC

L3Harris Technologies Inc. shares are higher in after-hours trading, reflecting positive market sentiment amid decreased expectations for a Federal Reserve interest rate hike.

2026. aug. 13. 23:51 UTC

StoneX Group Inc shares are lower in after-market hours, with no specific news identified. The asset remains near the lower end of its one-month trading range.

2026. aug. 13. 23:51 UTC

Asia equity markets show mixed performance as Japan's Nikkei rises on tech optimism and potential rate hikes, while China's Shanghai Composite dips amid geopolitical tensions and falling oil prices; U.S. jobless claims exceed expectations, softening inflation outlook.

2026. aug. 13. 23:51 UTC

Global equity markets rise, led by U.S. mega-caps, while mixed economic signals emerge from jobless claims and inflation data.

2026. aug. 13. 23:51 UTC

Mixed trading in European equities as UK GDP growth exceeds expectations while industrial production shows weakness amidst fluctuating oil prices and trade balance concerns.

2026. aug. 13. 23:51 UTC

U.S. equity indices remain flat as investors weigh mixed economic signals, rising jobless claims, and easing inflation amid geopolitical tensions and falling oil prices.

2026. aug. 13. 23:51 UTC

Australia's Westpac Consumer Confidence Report Set for August 18 Amidst Cautious Market Sentiment and Inflation Concerns.

2026. aug. 13. 23:51 UTC

Michigan Consumer Sentiment Report Set for August 14, Forecasted at 54.5 Amid Cautious Optimism Following Stable Inflation Data

2026. aug. 13. 23:51 UTC

US Business Inventories MoM data for June 2026 set to release on August 14, with a modest increase of 0.1% anticipated amid cautious market sentiment and inflation concerns.

2026. aug. 13. 23:51 UTC

Cautious Market Awaits July 2026 Building Permits Data Amid Ongoing Construction Sector Weakness and Rising Costs

2026. aug. 13. 23:51 UTC

NIO Inc shares are higher in after-market trading, reflecting broader market trends amid unchanged producer prices and reduced interest rate hike expectations.

2026. aug. 13. 23:51 UTC

Digital Realty Trust Inc shares are higher in after-market trading, reflecting broader market optimism following recent economic data and a recovery from earlier lows.

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

105.83% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 8.83 USD  105.83%

Magas 11 USD

Alacsony 5 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

5

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat